ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Psychomotor Agitation
Brain Diseases
Neurodegenerative Diseases

Alzheimer's Disease trials near London, England, GBR:

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...

Enrolling
Alzheimer's Disease
Alzheimer's Disease, Familial
Drug: lecanemab

Phase 3

The Washington University
The Washington University

London, Greater London, United Kingdom and 5 other locations

and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...

Enrolling
Prodromal Alzheimer's Disease
Alzheimer's Disease
Biological: Placebo
Biological: ACI-24.060 at Dose D

Phase 1, Phase 2

AC Immune

London, United Kingdom and 18 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

London, Greater London, United Kingdom and 37 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

London, Greater London, United Kingdom and 37 other locations

multiple intravenous (IV) doses of IBC-Ab002 in persons with early Alzheimer's disease. The study will have both Single- and Multip...

Enrolling
Alzheimer's Disease
Other: Placebo
Biological: IBC-Ab002

Phase 1

Immunobrain Checkpoint

London, United Kingdom and 10 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

London, United Kingdom and 117 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

London, United Kingdom and 102 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Phase 2

Acumen Pharmaceuticals

London, Greater London, United Kingdom and 96 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

London, United Kingdom and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

Phase 3

Eisai
Eisai

London, United Kingdom and 246 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems